Q-omics provides the consensus-scored TET2 profile across patient tissues and cancer cell-line models. TET2 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TET2 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, TET2 RNA expression shows 21,079 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where TET2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TET2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TET2 survival associations across molecular data types. TET2 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TET2 RNA expression–survival associations across cancer types. High TET2 expression shows unfavorable associations in UVM and ACC, but favorable associations in KIRC, HNSC, GBM and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TET2 RNA expression.
This table summarizes TET2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for TET2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TET2 shows lower tumor expression in COAD and THCA and higher tumor expression in BLCA, CHOL, KIRC and LIHC. The COAD box plot shows higher TET2 RNA expression in normal versus tumor tissue (log2 FC = −0.582, t-test p < 0.001).
This table shows molecular features associated with TET2 in patient tissues and cancer cell lines. In patient samples, TET2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TET2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
